entrectinib

Drug Overview

Entrectinib is a breakthrough Targeted Therapy and “Smart Drug” designed to treat cancers based on their specific genetic features rather than where they started in the body. It is a highly specialized medicine that belongs to a class of drugs known as kinase inhibitors.

• Generic Name: Entrectinib
• US Brand Names: Rozlytrek®
• Drug Class: Kinase Inhibitor (specifically Tropomyosin Receptor Kinase [TRK] and ROS1 inhibitor)
• Route of Administration: Oral (Capsules)
• FDA Approval Status: FDA-approved for specific solid tumors and lung cancers.

What Is It and How Does It Work? (Mechanism of Action)

Entrectinib is a precision medicine that acts like a “master switch” to turn off signals that tell cancer cells to grow and multiply. It is specifically designed to cross the blood-brain barrier, making it effective for treating cancers that have spread to the central nervous system.

Molecular Level Activity

At the molecular level, entrectinib targets three specific proteins: TRK (A, B, and C), ROS1, and ALK.

1. NTRK Gene Fusions: In some cancers, a gene called NTRK accidentally joins with another unrelated gene. This is called a “fusion.” This fusion creates abnormal TRK proteins that are always “on,” sending constant growth signals to the cell. Entrectinib binds to the ATP-binding site of these abnormal proteins, blocking the signaling pathways (such as PI3K and MAPK) that lead to uncontrolled cell division.
2. ROS1 Inhibition: In certain lung cancers, the ROS1 gene undergoes a similar fusion. Entrectinib blocks the ROS1 protein, which stops the cancer from receiving survival and growth messages.
3. CNS Penetration: Unlike many other drugs, entrectinib is “CNS-active.” It remains inside the brain and spine at high enough levels to kill cancer cells that have migrated there, which is a common challenge in advanced oncology.

FDA-Approved Clinical Indications

Entrectinib is used for “tumor-agnostic” treatment, meaning it is approved for any solid tumor that has a specific genetic marker, regardless of the organ.

Oncological uses:

• NTRK Fusion-Positive Solid Tumors: For adults and pediatric patients (12 years and older) with solid tumors that have an NTRK gene fusion without a known resistance mutation, and whose cancer is metastatic or where surgery is likely to cause severe complications.
• ROS1-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC): For adults with lung cancer that has spread and carries the ROS1 genetic change.

Non-oncological uses:

• There are currently no FDA-approved non-oncological uses for this medication.

Dosage and Administration Protocols

Entrectinib is taken once daily by mouth. The dose depends on the patient’s age and the specific condition being treated.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: No specific starting dose adjustment is required for mild liver issues, but patients with moderate to severe impairment should be monitored closely for increased side effects.
• Renal (Kidney) Insufficiency: No dose adjustment is needed for patients with mild to moderate kidney disease.
• Toxicity Management: If severe side effects occur, doctors may reduce the dose in 200 mg increments or pause treatment.

Clinical Efficacy and Research Results

Clinical trials conducted between 2020 and 2025 (such as the STARTRK-2 and ALKA-372-001 studies) have shown significant success rates for patients with these rare genetic markers.

• Response Rates (NTRK): Data shows an Overall Response Rate (ORR) of approximately 57% to 67% across various solid tumor types.
• Response Rates (ROS1): For patients with ROS1-positive lung cancer, the ORR was observed at nearly 67% to 78%.
• CNS Efficacy: In patients whose cancer had already spread to the brain, entrectinib showed an intracranial response rate of over 50%, highlighting its ability to treat brain metastases effectively.
• Duration of Response: Many patients maintained their response for a median of 12 to 20 months before the disease showed further progression.

Safety Profile and Side Effects

While entrectinib is a targeted therapy, it can still cause side effects because TRK proteins also play a role in the normal nervous system.

Black Box Warning:

• There is currently no Black Box Warning for entrectinib. However, it carries serious warnings regarding heart failure and bone fractures.

Common side effects (>10%)

• Fatigue: Feeling unusually tired or weak.
• Dysgeusia: A change in the sense of taste (metallic or bitter taste).
• Edema: Swelling, usually in the legs or hands.
• Dizziness: Feeling lightheaded or unsteady.
• Constipation: Difficulty with bowel movements.
• Cognitive Changes: Confusion, trouble with memory, or hallucinations.

Serious adverse events

• Congestive Heart Failure: The drug may weaken the heart muscle.
• Bone Fractures: Increased risk of broken bones, even with minor injury.
• QT Prolongation: Changes in the heart’s electrical rhythm.
• Hepatotoxicity: Liver inflammation or damage.

Management Strategies: Patients experiencing dizziness should avoid driving. Weight gain or shortness of breath should be reported immediately as they may signal heart issues.

Research Areas

In the 2024–2026 research landscape, entrectinib is being studied in combination with other Immunotherapies to see if it can enhance the body’s overall immune response. Researchers are also investigating its use in “neo-adjuvant” settings—giving the drug before surgery to shrink tumors that were previously considered impossible to remove safely.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed:

• Biomarker Testing: A validated test (like Next-Generation Sequencing) must confirm the NTRK fusion or ROS1 positivity.
• Cardiac Screening: Baseline EKG and evaluation of heart function (Ejection Fraction).
• Liver Function Tests: To establish baseline health levels.

Precautions during treatment:

• Sun Sensitivity: The drug may make skin more sensitive to sunlight.
• Fracture Risk: Patients should be cautious with physical activities that could lead to falls.

“Do’s and Don’ts” list:

• DO swallow capsules whole; do not open, crush, or chew them.
• DO report any sudden weight gain or swelling to your doctor immediately.
• DON’T eat grapefruit or drink grapefruit juice, as it can increase the drug’s levels in your blood to dangerous amounts.
• DON’T stop taking the medication without consulting your oncologist, even if you feel better.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Entrectinib (Rozlytrek) is a prescription medication that must be used under the supervision of a qualified oncologist. Always seek the advice of your physician regarding your specific diagnosis and treatment options. If you are experiencing a medical emergency, contact your local emergency services immediately.